Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Ditto on your post!
Echo20, we expect the following projected events will come to past:
-Approval for DengueCide® orphan status ~ 3Q 2013
-Well over 100 countries to approve "first in class" patent applications ~ 4Q 2013
projected Milestones - 2013
-cGMP/R&D Center Shelton CT integration completes ~ 4Q 2013
-Commision new cGMP plant ~ 4Q 2013 (equipment moved in/3 identical test batches)
-Receive initial results toxicology studies FluCide ~ 4Q 2013
-Prepare IND for submission to regulatory authorities ~ 4Q 2013
And then the expected and other surprise factors that you mention:
Up List, Correct figures and VOLUMES, deals with "Big Pharma"
About the, Buyout offer? I believe Theracour Pharma, Inc. contract with NanoViricides, Inc. is exclusive and it is not transferable. So yes, buyout is possible. Agreement would have to be reached with Theracour Pharma, Inc., a private company, to buy/obtain the "crown jewel", the patented "transformational-technology" that enables NanoViricides Inc. to develop the "shifting-paradigm of antiviral drugs".
"Nanoviricides are currently binary: they either work in humans as they have in animals, or they don't. IMO, there is nothing in between. If they work in humans, then $10 billion will be leaving $40 billion on the table. Pharmassette went for $11 billion with one drug completing Phase 2 and ready for Phase 3. Do the math with that and 5 antiviral drugs plus 200 more in development." ~ BigKahuna
NanoViricides Signs Agreement with Public Health England for Testing of Various NanoViricides Against Specific Viruses of Current Concern
NanoViricides, Inc. (the "Company") has signed a “confidential disclosure agreement” with Public Health England, the British government’s equivalent of the U.S. Centers for Disease Control. The agreement will allow the scientists at Public Health England to develop a specific proposal for the testing of different nanoviricides, such as FluCide®, against viruses of “mutual interest” to both organizations. More specifically, the first two viruses of mutual interest are H7N9, the influenza virus now circulating in China as well as the latest version of the coronavirus, now circulating in the Middle East. It is now referred to as the MERS virus.
From the individual posts I gather we were hit by a near perfect storm. First, people were complaining about inaccurate readings of NNVCD pps or no readings at all. The institutional investors are watching the hawks flying into their territory. Seems like for many today it was like flying without instruments. Second there was a pennies gap between yesterday and day before yesterday and that got filled. Third, some shorts wanted a way out, they pushed and they got it. But ultimately, the transformational-technology supporting Nanoviricides, Inc. won't be denied. We will resume the climb in pps and steadily soar!
FORZANANO, the drugs are...
I-
Telaprevir
Boceprevir
I contracted Hepatitis C in 1979 from 4 blood transfusions
A liver biopsy in 1994 revealed Chronic Hepatitis C. After Cancer, Radiation Therapy, Chemotherapy and now Hep C, my liver was in bad shape. The medical establishment advised me to get my papers in order and expect to live another 3 to 5 years, and hope that something would come along to help.
19 years later, Lloyd has been virus free for 17 years., with no detectable virus.
Triumph Over Hepatitis C is a graphic, turbo charged saga, depicting actual events in my life as I struggled with the menace, Hep C.
The Remedy, The Option of Alternative Medicine that saved my life is documented in the revised edition of my Book. Now with the dosage information and extended commentary by medical doctors and Ph.Ds. ~ LloydWright.org
FORZANANO, here is Mayo Clinic on new Hepatitis C virus treatment video. The video is May 20, 2011
To combat insomnia, if any, (10) 8oz. glasses of water. Nausea? Alkaline water. Your wife is right.
Perhaps you may recognize of of the two drugs mentioned in the video.
Another Robin Williams masterful performance and looking forward to another masterful performance from NNVC tomorrow!
Nanoviricides, Inc. management/insider/advisers group really know how to do a "U" turn after a RS drop! Nothing like this...
When asked why he has made these investments, he explained that
“As I became familiar with the technology and the various on-going programs that the Company has, it became apparent that the potential was nothing short of amazing. Dr. Diwan explained to me how it would be possible to create a novel drug against a previously unknown virus in a matter of weeks. The NanoViricides team has demonstrated this capability by creating potential drug candidates for the MERS human Coronavirus in just a few weeks. I was impressed by the business acumen of the senior management as demonstrated by their ability to bring in six commercially important drug candidates in the Company’s pipeline, in a relatively short time frame. I was also impressed by their receiving orphan drug designation for the dengue/dengue hemorrhagic fever drug candidate, the interest shown by the British Government Agency in a collaboration on MERS and H7N9, as well as the progress they’ve made in the construction of the new R&D and cGMP pilot production facility. Although I have known Dr. Seymour professionally for many years, I was introduced to the Company by my sister, Vivien Boniuk, MD, also an ophthalmologist, who had performed the animal studies on the Company’s drug candidates for adenovirus and herpes virus infections of the eye.” ~ Dr. Milton Boniuk
"...I was introduced to the Company by my sister, Vivien Boniuk, MD, also an ophthalmologist, who had performed the animal studies on the Company’s drug candidates for adenovirus and herpes virus infections of the eye." ~ Dr. Milton Boniuk
Yes, it happens to me in the morning, sometimes I misplace things like that NOTE. GreaHave a good one!
Thanks for pointing this out! I read other posts here that support the idea. The future of NanoViricides, Inc. is one of VAST opportunities. And we are sailing right along with it! Behold, a retirement fund of ONE!
Comes from a "Piecemaker" post that references a Patrick Cox newsletter...2011
Patrick Cox writes an expensive newsletter in which he identifies companies he believes are "Gamechangers". BTX and NNVC are but two of several. Below is an update he shared with subscribers last month (found this on another board). The link you posted reminded me of this, so I wondered if it's part of the problem he identifies below...
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=60304627
I posted the part that pertains to NNVC in an attempt to ward off the "NNVC stock warmongers", but this board is guarded by the NNVC "300". No worries.
Quantified by the BigKahuna, "5 antiviral drugs plus 200 more in development." http://investorshub.advfn.com/boards/read_msg.aspx?message_id=91019400
The future of NanoViricides, Inc. is VAST.
Nanoviricides, Inc. is our "bridge over troubled water". Here are some words of wisdom from Patrick Cox, words that do not get old.
The more transformational a technology is, the easier it is to get people doubting it. Take, for example, NanoViricides (OTCBB: NNVC) NOTE: It used to be in the OTCBB:NNVC and now it will soon be, as far as I know, in NYSE MKT LLC. This company's remarkable technology combines nano-sized polymer structures with biological ligands -- nanoviricides. The ligands "signal" to the target viruses that they are inside human cells. The viruses attack these nanoviricides and are, in turn, dismantled and harmlessly removed.
Here are some more words from Patrick Cox...
I know this sounds like science fiction.
In fact, the company has proven the technology over and over in conjunction with some of the world's most important scientists. It's real. It works, and it will revolutionize the way medical science deals with a broad range of viruses. Viruses, incidentally, are only now beginning to be truly understood. It appears, in fact, that they play roles in conditions we never suspected, ranging from obesity to chronic fatigue syndrome. So NanoViricides' future is VAST.
Nevertheless, there is a minor industry based on convincing investors that NanoViricides is some sort of hoax. For a long time, if you did a Google search on the company name, the top paid search results were screaming claims that the company was a scam. If you searched my name, it often returned accusation that I was part of the NanoViricides scam.
I wish, by the way, that I did own part of NanoViricides. I am prohibited by my arrangement with Agora Financial.
Dr. Eugene Seymour told me that he had tried to contact Google about putting an end to this slander, but could never get a response. Google's informal corporate slogan, by the way, is "Don't be evil."
Anyway, there are several reasons that people might attack a company in this manner. Some are probably simply trying to sell a report about NanoViricides, or at least get credit card information from people foolish enough to fall for the trick.
Sometimes, however, these tactics are part of a broader short attack. Many of you know, in fact, that these short attacks are taking place because you have been offered money to "rent" your shares. I hear about it constantly, and this does not happen to just NanoViricides. The last time I reported it, Pro-Pharmaceuticals was being targeted.
In general, the greater the company's potential, the more attractive it is to short attackers. If a company has generated a lot of "buzz," it is likely that a lot of "traders" have decided to buy shares. These people often know nothing about the company's management, technology or market potential. They're just surfing trends.
As a result, groups that specialize in short attacks can manipulate them. These groups are expert at spreading rumors. They seem to have people planted on the boards who can say just the right thing at just the right time to trigger a stampede.
When I lived in Silicon Valley, I knew quite well the man who was then Steve Jobs' CFO. He frequently described his job in terms of warfare. I was skeptical at first, but he convinced me that a group of people were waging war against him and his company. If he didn't fight back, they would succeed.
Why would anybody attack a company run by Steve Jobs? They did so because sophisticated traders, as you know, can make money by driving a stock price down. In the age of the Internet, with the means to reach millions of investors, this has become a serious problem. Normally, I try to ignore these attacks because they usually don't hurt the companies they attack. They hurt the investors who sell their stock at low prices...
...Sail on silver girl, Sail on by, Your time has come to shine, All your dreams are on their way, See how they shine, If you need a friend, I'm sailing right behind... ~ Simon and Garfunkel
Thanks FORZANANO! The world is watching and waiting. The "good doctors" are aware of that and I believe the FDA and competition as well. BASi Toxicology and Safety studies coming. Let it be a parabolic climb!
Interesting indeed. I believe the second half of September will bring the "good news" to continue going higher. NanoViricides, Inc. is about the "shifting-paradigm of antiviral drugs" and we should always be mindful of that. Good luck to you with your calculations!
Thank you. Tomorrow we'll find out. Then there's Thursday and there is something about Fridays with this stock...optimistic Monday "good news" coming.
EW analysis? I see 'DaysOntheBeach' post. I think it will be fun. However I would heed the advise of several here, buy now because bargain prices will soon be gone! $24/s to $30/s by Christmas? Not on crack. Perhaps optimistic!
After $5.19/s I see no resistance, not even at $8.39. Does anyone have an idea what the resistance level is after $8.39? Is it $9.20/s?
http://www.barchart.com/cheatsheet.php?sym=NNVCD The information is not for me. Thank you.
NYSE Amex LLC was renamed NYSE MKT LLC. Thank you for the correction.
I will be checking the NYSE Listings Directory: http://www.nyse.com/about/listed/lc_ny_overview.html every morning until...we are officially listed!
If Nanoviricides, Inc. applied to join the AMEX, then the Listing Requirements of the American Stock Exchange - NYSE-Amex can be found here: http://www.venturelawcorp.com/listing_requirements_amex.html
NYSE Listings Directory: http://www.nyse.com/about/listed/lc_ny_overview.html
This Virtually Unknown Stock Could Double Traders' Money
StreetAuthority Network
In a globally-connected world, viruses can spread quickly. From influenza to dengue fever to herpes to HIV, viral contagions can spread at an alarming pace. Trouble is, doctors researching these viruses, known as virologists, have found it quite difficult to identify permanent cures. For example, even though doctors completely understand how the flu virus works, millions of people still come down with a flu bug every year. And in some instances, the flu can have fatal consequences.
But little-known NanoViricides (NNVCD) may have "cracked the code" when it comes to viruses. The company still has a lot to prove, as is the case with any young biotech stock that trades for around $1. But it appears to be making progress, and if it can deliver on at least one of its several drugs in development, then the upside could be significant.
Though the company has been around since 2005, the past year has been quite eventful, and NanoViricides is seeing increasing trading volume and a rising share price.
source: http://finance.yahoo.com/news/virtually-unknown-stock-could-double-013000126.html
Moreover, a steady stream of capital infusions over the years has caused the share count to swell to 163 million. Investors should assume that the company needs to issue at least 40 million or 50 million more shares in coming years to further fund clinical trials. The company could also choose to sign a marketing deal with a large drug company, which would likely provide an equity infusion in exchange for sales rights, eliminating the need for further dilution.
Should we make assumptions? If I am to make assumptions, I will assume the CEO of Nanoviricides, Inc. and the insider long-term investors know best.
"...we are a company...with the ability to rapidly create drugs, and when I say rapidly create drugs I'm talking about weeks instead of years..." ~ Dr. Eugene Seymour, CEO Nanoviricides, Inc.
"by the way, I'm sure that when you think human trials for drugs you think of hundreds of millions of dollars and years of time, well in this case because the disease only lasts a week, two weeks,...that it is possible to complete human trials in the space of a few short months...four parts to the human trials" ~ Dr. Eugene Seymour, CEO Nanoviricides, Inc.
NanoViricides reports it has successfully improved HIVCide drug candidate in cell culture studies (NNVC) 3.60 : Co reported that it has successfully improved upon its previous lead anti-HIV drug candidate, based on cell culture studies. An improved broad-spectrum anti-HIV nanoviricide that inhibited two distinctly different types of HIV-1 viruses equally well has been identified. This drug candidate also exhibited a very large therapeutic index. The co has previously reported that it is optimizing the anti-HIV drug candidate. The co reported that it has identified an improved broad-spectrum anti-HIV ligand, based on the previous best ligand from the 2011 study. Also, both of these broad-spectrum ligands, when connected to a different backbone polymer than in the 2011 study, have shown substantially improved inhibition of two different types of HIV-1 virus in a standard cell culture study of virus neutralization and inhibition. HIV-1 Ba-L, a CCR5-using strain as well as HIV-1 IIIB, a CXCR4-using strain, were both inhibited equally well by these two different nanoviricide drug candidates in the standard MAGI HIV Antiviral Assay. The present cell culture data also showed that the two nanoviricides under study were safe to cells at far greater levels than the level needed for therapeutic effects.
Now that FluCide and DengueCide are on parallel tracks to the Human Trials (2014), as previously projected, there is time to work on optimization of the next drug candidates, one of the leading candidates is HIVCide. Good management, anticipating! Very good news! More PRs are coming our way!
“We have developed a small chemical ligand that mimics both the mammalian (or a-2,6-) and avian (or a-2,3) forms of the native sialic acid receptor of influenza viruses. We can design a nanoviricide to exhibit several ligands at a single point, and each nanomicelle may exhibit several hundred ligands on its small surface. The ligands are designed to look very much like (mimic) the sialic acid to the influenza viruses, and the high density of the ligands would force the virus to land onto the nanoviricide and get destroyed by the hidden ‘tails’ of the nanomicelle that snap out and merge into the viral surface lipid coat.” ~ Dr. Anil R. Diwan, PhD, President and Chairman Nanoviricides, Inc.
“The farther back you can look, the farther forward you are likely to see.” ? Winston Churchill.
"Something that doesn't yet exist, is posing a threat to the entire world" ~ Pandemic
"The one thing that sticks with me, about the "Pandemic", is that everybody knew someone who died" ~ Pandemic BBC Documentary
"people couldn't move, they couldn't talk" ~ John Oxford, Professor of Virology, University of London
"...we are a company...with the ability to rapidly create drugs, and when I say rapidly create drugs I'm talking about weeks instead of years..." ~ Dr. Eugene Seymour, CEO Nanoviricides, Inc.
"by the way, I'm sure that when you think human trials for drugs you think of hundreds of millions of dollars and years of time, well in this case because the disease only lasts a week, two weeks,...that it is possible to complete human trials in the space of a few short months...four parts to the human trials" ~ Dr. Eugene Seymour, CEO Nanoviricides, Inc.
For the benefit of all forum participants, here is a video to illustrate the magnitude of the damage this HVC virus can cause. http://www.doctoroz.com/videos/animation-hepatitis-c
I am sure doctors are on top of this disease, with the best medicine available today, to slow down or manage the life-threatening effects.
Take a look at WebMD on Hepatitis C http://www.webmd.com/hepatitis/hepc-guide/managing-hepatitis-c
People with Hepatitis C often have a hard time sleeping, especially during treatment. Toxins and stimulants are concentrated in the organism by dehydration and can cause insomnia and loss of restorative sleep, which is important. http://www.phosphenism.net/insomnia.html
Our diet, in the U.S., is acid. It may be less acid in Europe/Italy. For me, drinking ten glasses (8oz.) of alkaline water a day helps me stay hydrated enough to induce a restful sleep at night. I am not a doctor/physician but I can read and (10) glasses a day of alkaline water is good for me and I am able to drink (2) or (3) glasses first thing in the morning (good after about 6 to 8 hours of sleep without a drop). No nausea because it is not acid water but alkaline.
I believe Nanoviricides, Inc. will be soon in the market. HCV-Cide will be likely one of the therapeutic drugs next to follow, after FluCide and DengueCide. Something positive will happen before Phase I or after, whereby "Big Pharma" will strike a deal but that deal or deals, will have to be favorable to NanoViricides, Inc.. Unprecedented deals will be required for the "shifting-paradigm of antiviral drugs."
The U.S. FDA has already provided the "roadmap" (pre-IND meeting) for IND and to move FluCide through the clinical trials, the four phases. That is the reason I was asking the opinion of some in this forum because I may have missed a PR that would have clarified that statement. I believe Dr. Seymour purposely paused/emphasized and said, "...and by the way, I'm sure that when you think of human trials for drugs you think of hundreds of millions of dollars, and years of time. Well in this case, because the disease only lasts a week...two weeks, that it is possible to complete human trials in the space of a few short months...four parts to the human trials"? http://investorshub.advfn.com/boards/read_msg.aspx?message_id=91851826
May God keep your dad in stable health for the years to come, so that he may become a beneficiary, as well as many others, of the life-saving medicine (HCV-Cide) of Nanoviricides, Inc.. I always write as if US FDA review/approval were a forgone conclusion. But then I read about the nanoviricide nanoparticle, its components, and I say to myself, why not? http://investorshub.advfn.com/boards/read_msg.aspx?message_id=91812469
Those Italian Dolomiti, impressive!
Exactly the kind of thing us long-term investors here needed to hear. Sales to an in-the-know, already invested, long-term holders here is extremely unlikely to result in short-term selling pressure as result of the 'new' issue of shares. Institutional holders are never bad either. ~ drKazmd65
“We are extremely pleased that our long term equity-oriented supporters led with the majority of the investments we received,” said Eugene Seymour, MD, MPH, CEO of the Company, adding, “We believe that most of the remaining funding came from new high quality equity-oriented institutions and accredited investors, who we expect are also becoming long term supporters that share our vision of developing paradigm-shifting antiviral drugs.”
“We believe that most of the remaining funding came from new high quality equity-oriented institutions and accredited investors, who we expect are also becoming long term supporters that share our vision of developing paradigm-shifting antiviral drugs.” said Eugene Seymour, MD, MPH, CEO
FORZANANO, God willing, through the science and life-saving medicine of Nanoviricides, Inc. soon in the market, your father's health will be positively restored.
Nanoviricides, Inc. does not employ tiny hands or nano-hands/fingers to plug-in several ligands at a single point on the nanomicelle small surface.
“We have clearly demonstrated that the design platform technology for nanoviricides allows development of powerful broad-spectrum antiviral drugs,” said Anil R. Diwan, PhD, President and Chairman of the Company,
“We are very excited about this association with the Harris Lab [...] We will now be able to rapidly advance our anti-dengue therapeutics program.” —Eugene Seymour, CEO of NanoViricides
“We are rapidly advancing towards our goal of filing an IND with the FDA for Influenza based on the guidance we received in our previous pre-IND meeting with the FDA,” said Anil R. Diwan, President of the Company.
I totally agree I Need Help. I would not be surprised if today NNVC opens on or above the 50 DMA ($3.62) and closes with higher low. Friday is fast approaching and just like the R/S surprise, we never know what other "good surprises" Monday will bring. Have a great day!
I have a question. When possible, please watch the video and give us your opinion as to why would Dr. Seymour states the following, "...and by the way, I'm sure that when you think of human trials for drugs you think of hundreds of millions of dollars, and years of time. Well in this case, because the disease only lasts a week...two weeks, that it is possible to complete human trials in the space of a few short months...four parts to the human trials"?
Fast forward the video to 19:00 minutes (for some context) or by 19:50 minutes to listen to the particular statement by Dr. Seymour.
A reverse split is usually, but not always, a sign that a company is in trouble. Companies who's share price has fallen so much that they will be delisted by an exchange will often do a reverse split to make the price per share high enough to avoid delisting. - See more at: http://wiki.fool.com/Reverse_split#sthash.ch0wbQ3q.dpuf
The Registrant has elected to effectuate the Split in order that the price of the Common Stock qualify for listing on a national securities exchange. The Amendment was unanimously approved by the Board of Directors so that the Common Stock would comply with such listing requirement.
This makes it more difficult for the small investor to quickly accumulate 1000s of shares while the institutional investors will finally be able to jump in and drive the price up, possibly at a faster rate than before. Fewer shares with equal or greater demand (institutional investors)should make possible the climb in pps at the same rate, if not faster.
Nanoviricides, Inc. has nothing to hide and will meet requirements of new stock exchange. It has the money for Phases I/IIa. We will see that in required reporting.
More good news are coming our way.
Thanks Leifsmith. I, like many others that post here, see Nanoviricides, Inc. as a great opportunity.
It is my investment, it is my business as it is the business of many that have a vested interest in the success of Nanoviricides, Inc.. Why wait for the company to spend money on taking the message to the people? Let us all do our best to take the message out to the people. "Big Mo" has the resources to get key information for themselves. I have no problem with that. But, what happens when the "Lilliputians", like myself, start getting the picture, and start jumping in? "Big Mo" will have to implement their buying program sooner than later. Just speculating here!
I have been writing to many people, my family, friends. I was donating platelets yesterday and spoke with one of the phlebotomists, while others nearby may have been listening. He took notes down. I gave similar advice as drkazmd has before, go to thelion.com, enter stock symbol NNVC and you will be in the NNVC forum. If you want to post questions, create a user ID and post your questions. Otherwise read all you can, make it your business to understand all aspects well, visit the forum frequently and do it fast because Nanoviricides, Inc. is "laying down tracks for a railway" to the marketplace. http://investorshub.advfn.com/boards/read_msg.aspx?message_id=91571843
As Puffer commented yesterday, there is great potential built on NNVC! http://investorshub.advfn.com/boards/read_msg.aspx?message_id=91808045
There is great anticipation building on Nanoviricides, Inc. and rightfully so!
A correction to my post this morning: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=91812469
But how or what is Nanoviricides, Inc. employing to construct a nanoviricide? Basically,a nanoviricide is constructed by chemically attaching virus-binding ligands to a polymeric (water-loving) micelle. Like "LEGO pieces", Nanoviricides Inc., is plugging-in the "ligands", about two hundred of them, to the small "hydrophilic" surface of each micelle. For instance, a dose of FluCide, one of the two clinical candidates (2014), contains about 75 trillion nanomicelles (nanoparticles) in a teaspoon. The human body has about 100 trillion cells. As you may know, the various tissues of the human body are between 75% and 95% water. This water is used as a way of transporting nutrients and other substances in the body.
It is mind boggling! About two hundred "ligands" on the small surface of each nanomicelle! What are they using, nano-hands?
When Flu Viruses Attack!
Learn how flu viruses get into and out of your cells using Hemagglutinin (Holds) and Neuraminidase (Nicks) proteins on their surface.
Hard questions were asked by Nanoviricides, Inc. because so many of the problems worth solving in life are hard. If they were easy, someone else would have solved them before you got to them.
"...Polymer nano-particles or nanomicelles are used as carriers for the delivery of drug. It has been one of the most attractive areas because of its scientific value and potential of application. The nano-micelles are constructed from very low toxicity substances. They have roughly the same toxicity as water. Drink too much water and it's toxic; the same with NanoViricides materials. NanoViricide micelles are constructed from materials found normally in the metabolic process. So, the nano-micelle is broken down in much the same way. The targeting ligand does not attack human cells or animal cells. It binds to sites on virus cells that the virus uses to bind with human cells..." ~ Dr. FeelGood
Since we are not anticipating a price drop then, why?
Reverse Stock Split Explained
On any stock exchange, share prices rise and fall. From time to time, a stock's price may drop to a point the company feels is too low to attract investors. A reverse stock split is a way to raise the share price, the better to pull in new investors. In a reverse stock split, the company consolidates shares to reduce the number of shares outstanding. For example, in a two-to-one reverse split, you would receive one new share for every two old shares you owned, and the new share would be worth twice as much. Depending on state law and company bylaws, a reverse stock split may not require shareholder approval. The company's board of directors can decide to effect the split on its own.
- See more at: http://wiki.fool.com/Steps_for_a_Reverse_Stock_Split#sthash.ZH7bkYfh.dpuf
Anticipated Effects of Reverse Stock Split
Effect on the Market Price of the Common Stock. Although the Company expects that the reverse stock split will result in an increase in the market price of the common stock, the reverse stock split may not increase the market price of the common stock in proportion to the reduction in the number of shares of common stock outstanding or result in a permanent increase in the market price. For example, based on the closing price of the common stock on December 4, 2009 of $0.41 per share, if the stockholders approve, and the Board of Directors implements, the reverse stock split, there can be no assurance that the post-split market price of the common stock would be $2.05 (5x current price) per share or greater. The market price is dependent upon many factors, including the Company’s performance, prospects and other factors detailed from time to time in the Company’s reports filed with the SEC. If the reverse stock split is accomplished and the market price of the common stock declines, the percentage decline as an absolute number and as a percentage of the Company’s overall market capitalization may be greater than would occur in the absence of a reverse stock split. In many cases, the market price of a company’s shares declines after a reverse stock split.
Effect on the Market for the Common Stock. If the Company is able to maintain the listing of its common stock on NASDAQ, the Company would not suffer the potential loss of liquidity resulting from delisting. Although the Company believes that a higher stock price may help generate investor interest, there can be no assurance that the reverse stock split will result in a per share price that will attract institutional investors or investment funds or that the share price will satisfy the investing guidelines of institutional investors or investment funds. In addition, the reduced number of outstanding shares of common stock resulting from the reverse stock split could adversely affect the liquidity of the Company’s common stock. As a result, the trading liquidity of the common stock may be adversely affected by the reverse stock split.
Effect on Authorized and Outstanding Shares. Currently, we are authorized to issue up to a total of 100,000,000 shares of common stock, of which 35,141,884 shares were outstanding as of December 4, 2009.
more here: http://www.wikinvest.com/stock/Management_Network_Group_%28TMNG%29/Anticipated_Effects_Reverse_Stock_Split
JScott. Write to these guys...
http://www.specialtypharmacytimes.com/publications/specialty-pharmacy-times/2012/February-2012/Orphan-Drugs-Small-Markets-Big-Opportunity
http://www.danskbiotek.dk/sites/default/files/nyhedsbreve/dansk_biotek_medlemsmoede_21.11.12_praesentationer.pdf
http://www.marketwire.com/press-release/alnylam-pharmaceuticals-biomarin-pharmaceutical-inc-cytonet-set-speak-on-conducting-1727607.htm
If you are successful, they will contact Sanford C. Bernstein analysts to contact you. You can then direct them to publicly retract the aforementioned statements, statements you find "not factual", from their research. Good luck with that! It is your time and effort but I digress.
Hi nanopatent! I guess you've been away for a few days. Welcome back.
Treatment is simple alright.--- There is no specific medicine to treat dengue infection. If you think you may have dengue fever, you should use pain relievers with acetaminophen and avoid medicines with aspirin, which could worsen bleeding. You should also rest, drink plenty of fluids, and see your doctor. If you start to feel worse in the first 24 hours after your fever goes down, you should get to a hospital immediately to be checked for complications. --- And if you get caught with it a second time, get to the hospital right away and make sure you have made arrangements with the undertaker.
When DengueCide gets approved to market a person infected may spend a day, maybe two, at home just getting better by the hour. This a lot better than one week or two at the hospital. But I don't have to sell you on that. You've informed us about it yourself.
As daBoze has said before, "don't go away for to long because at the gates, waiting for an opportunity, are the Barbarians"
There are three things you may want to do:
1) Get a copy of the Sanford C. Bernstein analysts research directly from them
2) Find another research paper that counters their findings (not a blogger's opinion/inferences)
3) Someone that knows the Nanoviricides, Inc. CEO that counters the following - "Because Dengue can't be tested through a challenge protocol with patients inoculated with the virus (made sick with Dengue then treated), it may be approved with only small phase 1/2a under orphan drug/breakthrough." http://investorshub.advfn.com/boards/read_msg.aspx?message_id=91066231
What is more important?
Nanoviricides, Inc. is NOT the story of another multi-billion dollar "host-enhancing" vaccine. Far from it, it is all about a drug, trillions of nanoparticles with "a mechanism" that finds and destroys virus structures, the source of the problem. As the Cides inventor, Dr. Anil Diwan, describes it: “We have clearly demonstrated that the design platform technology for nanoviricides allows development of powerful broad-spectrum antiviral drugs,” said Anil R. Diwan, PhD, President and Chairman of the Company, “We have developed a small chemical ligand that mimics both the mammalian (or a-2,6-) and avian (or a-2,3) forms of the native sialic acid receptor of influenza viruses. We can design a nanoviricide to exhibit several ligands at a single point, and each nanomicelle may exhibit several hundred ligands on its small surface. The ligands are designed to look very much like (mimic) the sialic acid to the influenza viruses, and the high density of the ligands would force the virus to land onto the nanoviricide and get destroyed by the hidden ‘tails’ of the nanomicelle that snap out and merge into the viral surface lipid coat.”